US-based RNA editing technology developer Korro Bio has secured $116m in a series B round featuring Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria Real Estate Equities.
The round was led by Eventide Asset Management and included investment and financial services group Fidelity, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an unnamed healthcare specialist fund invested in the company, alongside all existing backers including Alexandria.
Founded in 2018, Korro is working on RNA editing technology intended to repair mutations responsible for genetically inherited diseases. Its lead development asset is aimed at Alpha-1 Antitrypsin Deficiency, a condition that leads to liver and lung disease.
The series B capital will allow the company to advance its lead programme and expand its pipeline. Joy Ghosh, portfolio manager at Eventide Asset Management, and Alex Silverstein, portfolio manager at Point72, have been appointed to its board of directors.
Wu Capital led Korro’s $91.5m series A round for in September 2020, when Alexandria Venture Investments, NEA, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management and existing backer Atlas Venture also took part.
The original version of this article appeared on our sister site, Global University Venturing.
